Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

AnuMed International, LLC

Has AnuMed International, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated August 20, 2024 concerning products containing semaglutide.

Letter facts

Letter date
August 20, 2024 (2024-08-20)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Manufacturer / API
Products named
Semaglutide Homeopathic FormulaMagnesium 50 mg Body CreamAnuMed™ 25mg Per Pump PROGESTERONE CREAMAnuMed™ 75mg Per Pump PROGESTERONE CREAMAnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMPAnuMed™ BIO-IDENTICAL BIO-EST 5mg Per PumpAnuMed™ 2.5 All Natural ESTRIOL CREAMAnuMed™ 5.0 All Natural ESTRIOL CREAMAnuMed™ Bio-Identical DHEA 20 CREAMAnuMed™ Bio-Identical DHEA 50 CREAM50,000 IU Vitamin D3+K2 CREAMTravel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health SupportVitamin C Booster - 2000mgImmune Booster 90 CapsulesVegan Vitamin D3 K2 60ct CapsulesB-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)2oz Vitamin C Booster Drops2oz Anumed Zinc DropsTurmeric Curcumin Drops 775mg with Black Pepper Extract
Violation categories
Unapproved new drugMisbrandingCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA cited unapproved new drug claims for numerous products, misbranding through misleading FDA approval or registration statements, and CGMP noncompliance rendering the drugs adulterated; no approved applications were in effect.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • unapproved new drugs
  • misbranded drugs
  • adulterated drugs (CGMP violations)

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.